started · updated
Upadacitinib approved for vitiligo and alopecia areata
The oral medication upadacitinib has received approval for the treatment of both vitiligo and alopecia areata. The drug functions as a small molecule that targets specific points in the immune system to block the transmission of inflammatory signals within cells.
In cases of alopecia areata, the treatment aims to relieve pressure on the hair follicle to promote hair regrowth. For vitiligo, it works by preventing the attack on melanocytes, the cells responsible for skin pigment, thereby allowing for the repopulation of pigmented cells.
Antonio Costanzo, Vice President of Sidemast and Director of Dermatology at Humanitas University, noted that while the drug is already approved for other indications, these two new uses address high patient demand. The availability of the treatment in Italy will depend on approval from the Italian Medicines Agency (AIFA), a process that typically takes less than a year.
Entities
AIFA · AbbVie · Antonio Costanzo · Humanitas University · SIDeMaST · Upadacitinib
Claims
What the coverage asserts, and how many sources carry each claim.
- [● 3 SOURCES] In vitiligo, the drug blocks attacks on melanocytes to allow skin repopulation with pigment-producing cells. www.cagliarilivetv.it · laragione.eu · canaledieci.it
- [● 3 SOURCES] The availability of the treatment in Italy depends on approval from the Italian Medicines Agency (AIFA). www.cagliarilivetv.it · laragione.eu · canaledieci.it
- [● 3 SOURCES] Upadacitinib has been approved for the treatment of both vitiligo and alopecia areata on the same day. www.cagliarilivetv.it · laragione.eu · canaledieci.it